Moreover, in future work, we intend to apply BX-795 and capivasertib to organoid or PDX models to further corroborate the conclusion that EMC2 sensitizes tumor cells to PDK1/AKT inhibition therapy, serving as a complement to existing in vivo and in vitro drug sensitivity experiments. Here, PDK1 is linked to neoplasm.